Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab in chronic graft-versus-host disease
NCT06585774Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jan 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Axatilimab + Corticosteroids with Placebo + Corticosteroids (2 arms). Primary endpoint: Event-Free Survival at 3 years. Started Jan 2025; status: recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06585774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585774.